Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medclair ABNGM:MCLR +0.33%71 Return-on-Tangible-Asset is 36.54% as of Mar. 2026. GuruFocus rates NGM:MCLR with a GF Score™ of 71/100 and a GF Value™ of kr2.35 (Modestly Overvalued). Among 856 Medical Devices & Instruments companies, Medclair AB ranks better than 89.6% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Medclair AB's annualizedNet Income for the quarter that ended in Mar. 2026 was kr15.02 Mil. Medclair AB's average total tangible assets for the quarter that ended in Mar. 2026 was kr41.12 Mil. Therefore, Medclair AB's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 36.54%.
The historical rank and industry rank for Medclair AB's Return-on-Tangible-Asset or its related term are showing as below:
NGM:MCLR'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -77.05 Med: -33.9 Max: 17.32
Current: 13.01
During the past 11 years, Medclair AB's highest Return-on-Tangible-Asset was 17.32%. The lowest was -77.05%. And the median was -33.90%.
NGM:MCLR's Return-on-Tangible-Asset is ranked better than 89.6% of 856
companies
in the Medical Devices & Instruments industry
Industry Median: 0.595
vs NGM:MCLR: 13.01
Medclair AB (NGM:MCLR) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Medclair AB Return-on-Tangible-Asset Related Terms
Medclair AB Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Medclair AB's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NGM:MCLR vs ABT, SYK, MDT: Return-on-Tangible-Asset Comparison
For the Medical Devices subindustry, Medclair AB's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medclair AB Return-on-Tangible-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Medclair AB's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Medclair AB's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 36.54% mean?
Medclair AB (NGM:MCLR) has a Return-on-Tangible-Asset of 36.54% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Medclair AB and its competitors. According to the industry distribution chart, Medclair AB ranks #89 out of 856 companies in the Medical Devices & Instruments industry, placing it in the top 10.4%.
Is Medclair AB's Return-on-Tangible-Asset too high?
Medclair AB's current Return-on-Tangible-Asset is 36.54%. The Medical Devices & Instruments industry median Return-on-Tangible-Asset is 0.60. Medclair AB's value of 36.54% is 6041.2% above this industry median. Based on the distribution chart, Medclair AB ranks #89 out of 856 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Medclair AB has a GF Score™ of 71/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medclair AB's Return-on-Tangible-Asset compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Medclair AB ranks #89 out of 856 companies for Return-on-Tangible-Asset. This places Medclair AB in the top 10% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 0.60. Medclair AB's value of 36.54% is 6041.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Devices & Instruments company?
The median Return-on-Tangible-Asset among Medical Devices & Instruments companies is 0.60, based on 856 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medclair AB's current Return-on-Tangible-Asset of 36.54% is 6041.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Medclair AB and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Asset is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medclair AB's current Return-on-Tangible-Asset is 36.54%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medclair AB stock overvalued right now?
Based on GuruFocus' analysis, Medclair AB (NGM:MCLR) is currently considered Modestly Overvalued. The stock's GF Value™ is kr2.35, compared to a current price of kr3.06 — trading 30.2% above its estimated fair value. The current Return-on-Tangible-Asset is 36.54% and 6041.2% above the Medical Devices & Instruments industry median of 0.60. Medclair AB's overall GF Score™ is 71/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Medclair AB (NGM:MCLR), the current Return-on-Tangible-Asset is 36.54% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medclair AB (NGM:MCLR) Overvalued in 2026?
Based on GuruFocus' analysis, Medclair AB stock appears to be overvalued.
The current stock price of kr3.06 is trading 30.2% above its estimated GF Value™ of kr2.35.
GuruFocus considers Medclair AB to be Modestly Overvalued.
Key valuation signals for NGM:MCLR:
Return-on-Tangible-Asset: 36.54%
GF Value™: kr2.35 vs. price of kr3.06 (30.2% above fair value)
Industry Position: 6041.2% above the Medical Devices & Instruments median (#89 of 856)
No single metric tells the full story. See the NGM:MCLR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medclair AB operates in healthcare industry. The company has two units: Central Destruction Unit (CDU) and Mobile Destruction Unit (MDU) decomposes the nitrous oxide entering the unit, transforming it to nitrogen (N2) och oxygen (O2). It also provide solutions for various N2O methods such as double mask, single mask, mouthpiece, or free flow, which ensures a safe work environment for healthcare professionals.
71GF Score
Get the complete analysis for NGM:MCLR
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NGM:MCLR has been successfully added to your 
